A Two-Part Pharmacodynamic Study to Compare VentaProst (Epoprostenol Solution for Inhalation Via Custom Drug Delivery System) Dosing to Conventionally Administered Aerosolized Epoprostenol Dosing in Cardiac Surgery Patients
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2018
At a glance
- Drugs Epoprostenol (Primary) ; Epoprostenol
- Indications Pulmonary hypertension
- Focus Pharmacodynamics
- Sponsors Aerogen
- 23 Oct 2018 Planned End Date changed from 1 Aug 2018 to 31 Jan 2019.
- 23 Oct 2018 Planned primary completion date changed from 1 Jun 2018 to 31 Jan 2019.
- 08 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.